Core Insights - Nurix Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on targeted protein degradation medicines aimed at improving treatment options for cancer and inflammatory diseases [3] - The company will participate in a fireside chat at the Jefferies Global Healthcare Conference on June 4, 2025, featuring its president and CEO, Arthur T. Sands, M.D., Ph.D., and CFO, Hans van Houte [1] Company Overview - Nurix's pipeline includes degraders of Bruton's tyrosine kinase (BTK) and inhibitors of Casitas B-lineage lymphoma proto-oncogene B (CBL-B), with a focus on enhancing immune cell activation [3] - The company is advancing multiple potentially first-in-class or best-in-class degraders and degrader antibody conjugates (DACs) in its preclinical pipeline [3] - Nurix has partnered with Gilead Sciences, Sanofi, and Pfizer, retaining options for co-development, co-commercialization, and profit sharing in the U.S. for several drug candidates [3] - The company utilizes a fully AI-integrated discovery engine and has significant expertise in ligase, providing a competitive advantage in translating targeted protein degradation into clinical advancements [3]

Core Viewpoint - Pulmatrix, Inc. is advancing its proposed merger with Cullgen, which is expected to close in June 2025, while divesting its clinical assets including the acute migraine candidate PUR3100 and its proprietary iSPERSE™ technology [1][3][2] Financial Performance - For the first quarter of 2025, Pulmatrix reported revenues of $0, a decrease of approximately $5.9 million compared to $5.9 million in the same period of 2024, primarily due to the completion of the PUR1900 Phase 2b clinical trial [11] - Research and development expenses decreased to less than $0.1 million, down approximately $3.5 million from $3.5 million in the first quarter of 2024, attributed to winding down the PUR1900 trial and other operational changes [12] - General and administrative expenses increased to $1.8 million, up approximately $0.2 million from $1.6 million in the first quarter of 2024, mainly due to costs related to the proposed merger [13] - As of March 31, 2025, the company's total cash and cash equivalents were $7.7 million, which is expected to be sufficient to fund operations through the anticipated merger closing [14] Product Pipeline and Technology - Pulmatrix's product pipeline includes PUR3100, an inhaled dihydroergotamine for acute migraine, which is Phase 2-ready following FDA acceptance of its IND application [7] - The company is also developing PUR1800, a Narrow Spectrum Kinase Inhibitor for chronic obstructive pulmonary disease, which has shown safety and tolerability in Phase 1b studies [6] - The iSPERSE™ technology enables the formulation of drugs into small, dense, and dispersible particles for efficient delivery to the lungs, enhancing therapeutic outcomes for various diseases [21][20] Merger Details - The merger agreement with Cullgen was initially reported on November 13, 2024, and amended on April 7, 2025, with the closing anticipated in June 2025, subject to certain conditions [3][4] - If successful, the merger will create a Nasdaq-listed company focused on targeted protein degradation technology, with three degrader programs in Phase 1 clinical trials [2]

Core Insights - Nurix Therapeutics, Inc. is advancing its clinical-stage biopharmaceutical efforts with the presentation of data from its ongoing Phase 1a/b clinical trial of bexobrutideg (NX-5948) for patients with relapsed/refractory chronic lymphocytic leukemia (CLL) and Waldenström macroglobulinemia at major scientific conferences [1][2] Group 1: Clinical Trial Presentations - Data from the Phase 1a/b clinical trial will be presented at the European Hematology Association 2025 Congress in Milan, Italy, from June 12–15, 2025, and at the 18th International Conference on Malignant Lymphoma in Lugano, Switzerland, from June 17–21, 2025 [2] - The EHA 2025 presentation will include findings on the rapid and durable clinical responses of bexobrutideg in relapsed refractory CLL, with Dr. Zulfa Omer as the presenting author [3] - An oral presentation at the 18-ICML will also cover updated findings from the Phase 1a study of bexobrutideg in relapsed refractory CLL, presented by Dr. Alexey Danilov [4] Group 2: Drug Profile - Bexobrutideg (NX-5948) is an investigational, orally bioavailable small molecule that acts as a degrader of Bruton's tyrosine kinase (BTK), currently evaluated in a Phase 1 clinical trial for relapsed or refractory B cell malignancies [6] - The drug is designed to penetrate the brain and is part of a broader strategy by Nurix to develop targeted protein degradation medicines aimed at improving treatment options for cancer and inflammatory diseases [7][8] Group 3: Company Overview - Nurix Therapeutics focuses on the discovery, development, and commercialization of targeted protein degradation medicines, positioning itself at the forefront of innovative drug design [7] - The company has a pipeline that includes BTK degraders and CBL-B inhibitors, with collaborations with major pharmaceutical companies like Gilead Sciences, Sanofi, and Pfizer [8]

Core Viewpoint - BeyondSpring Inc. reported its unaudited financial results for Q1 2025, highlighting advancements in its cancer therapeutics, particularly Plinabulin, and the SEED Therapeutics program, while also noting financial performance metrics. Financial Performance - R&D expenses from continuing operations increased by 21% to $874,000 in Q1 2025 from $721,000 in Q1 2024 [5] - G&A expenses from continuing operations rose by 30% to $1,736,000 in Q1 2025 compared to $1,334,000 in Q1 2024 [5] - Net loss from continuing operations was $2,584,000 in Q1 2025, a 24% increase from $2,080,000 in Q1 2024 [5] Clinical Developments - Plinabulin has been administered to over 700 patients, demonstrating a favorable safety profile and potential efficacy in patients who have progressed on PD-1/L1 inhibitors [2] - Early readouts in metastatic non-small cell lung cancer (NSCLC) and Hodgkin lymphoma showed durable responses warranting further evaluation [2] - The RBM39 molecular-glue degrader achieved complete tumor regression in Ewing sarcoma models and is on track for an IND submission mid-2025 [2][7] Corporate Updates - BeyondSpring owns approximately 40% of SEED Therapeutics, which operates independently and has been classified as discontinued operations for financial reporting [4] - The company reported a total asset increase from $34,315,000 as of December 31, 2024, to $37,104,000 as of March 31, 2025 [12][13] - The total liabilities increased from $48,600,000 to $49,771,000 during the same period [13] Shareholder Information - The net loss attributable to BeyondSpring Inc. was $4,477,000 for Q1 2025, compared to a net loss of $3,231,000 in Q1 2024 [15] - Basic and diluted earnings per share improved to $0.11 in Q1 2025 from a loss of $0.08 in Q1 2024 [15]

Core Insights - Nurix Therapeutics, Inc. has developed a DEL-AI platform that utilizes a first-in-class DEL Foundation Model trained on proprietary DNA encoded library data to predict novel binders for therapeutically relevant targets, including those previously deemed undruggable [1][2] - The DEL Foundation Model can perform virtual experiments to accurately predict experimental results, demonstrating a correlation between the model's success and the similarity of query sequences to the training set [2] Company Overview - Nurix is a clinical-stage biopharmaceutical company focused on targeted protein degradation medicines, aiming to improve treatment options for cancer and inflammatory diseases [6] - The company’s pipeline includes degraders of Bruton's tyrosine kinase (BTK) and inhibitors of Casitas B-lineage lymphoma proto-oncogene B (CBL-B), along with multiple preclinical candidates [6] Technology and Innovation - The DEL-AI platform integrates advanced machine learning with a collection of over five billion unique DEL compounds, enabling rapid identification of drug candidates for a wide range of proteins [2][4] - The development of the DEL Foundation Model was supported by collaboration with Loka and Amazon Web Services, utilizing AWS SageMaker for scalable infrastructure [3] Research and Development - Nurix's DEL-AI platform is designed to streamline drug discovery workflows, allowing for efficient identification of therapeutic candidates for both internal pipelines and partnerships [2] - The platform leverages extensive datasets from DEL affinity screens to identify binders for virtually any pharmaceutically relevant target [4]

Company Overview - Arvinas, Inc. is a clinical-stage biotechnology company focused on developing a new class of drugs based on targeted protein degradation [3] - The company is headquartered in New Haven, Connecticut and aims to improve the lives of patients with debilitating and life-threatening diseases [3] Financial Results and Corporate Update - Management will review the first quarter 2025 financial results and provide a corporate update during a live webcast on May 1, 2025, at 8:00 a.m. ET [1] - The webcast will be accessible under "Events and Presentations" on the investor page of the Arvinas website, with a replay available afterward [2] Drug Development Pipeline - Arvinas is advancing multiple investigational drugs through clinical development programs, including: - Vepdegestrant, targeting the estrogen receptor for patients with locally advanced or metastatic ER+/HER2- breast cancer [3] - ARV-393, targeting BCL6 for relapsed/refractory non-Hodgkin Lymphoma [3] - ARV-102, targeting LRRK2 for neurodegenerative disorders [3] Technology Platform - The company utilizes its PROTAC® (PROteolysis Targeting Chimera) protein degrader platform to develop therapies that selectively degrade and remove disease-causing proteins [3]

Core Insights - Kymera Therapeutics experienced a nearly 23% increase in share price this week, distinguishing itself in the volatile biotech sector due to positive announcements from the company [1] Company Developments - Kymera has initiated dosing in a phase 1b clinical trial for its investigational drug KT-621, which targets severe atopic dermatitis (eczema) [2][3] - The company expects to report data from the KT-621 trial in the fourth quarter of this year [3] - CEO Nello Mainolfi emphasized the significance of KT-621's advancement, highlighting the potential of their technology to transform treatment for complex immuno-inflammatory diseases through oral medications [4] Future Prospects - Kymera plans to reveal a new oral immunology program during its first-quarter earnings report, focusing on a high-value undrugged target for multiple autoimmune and rheumatic diseases [4] - The ongoing development of KT-621 is seen as a promising revenue opportunity for the company, given the commonality of atopic dermatitis [5]

Core Insights - Prelude Therapeutics has presented new preclinical data on its first-in-class SMARCA2 degrader PRT3789 and selective KAT6A degraders at the AACR Annual Meeting, highlighting their potential in treating cancers with specific mutations [1][2]. Group 1: SMARCA2 Degrader (PRT3789) - PRT3789 is a first-in-human SMARCA2 degrader that selectively induces deep and sustained degradation of SMARCA2, achieving high selectivity through a stable ternary complex formation with VHL [4]. - The resynthesis rate of SMARCA2 is 2-3 times slower than that of SMARCA4, enhancing the selectivity profile and contributing to a favorable safety profile observed in clinical studies [4]. - PRT3789 is currently under evaluation in Phase 1 and Phase 2 studies for patients with advanced solid tumors that have lost SMARCA4 [4]. Group 2: KAT6A Degraders - KAT6A is associated with cancer growth and is recurrently amplified in various cancers, making it a clinically validated target [5]. - Prelude has identified a series of first-in-class, sub-nanomolar, selective, and orally bioavailable KAT6A degraders that are advancing to candidate nomination [5]. - Preclinical data indicate that Prelude's selective KAT6A degraders drive significantly deeper anti-cancer responses compared to non-selective KAT6A/B inhibitors across multiple KAT6A-amplified tumors [5]. Group 3: Clinical Implications - The selective degradation of KAT6A is expected to improve hematological safety and provide robust single-agent activity compared to existing KAT6-targeted therapies [5]. - Prelude's KAT6A degraders exhibit sustained activity in various cancer models, including those resistant to endocrine therapy and CDK4/6 inhibitors, and show potential for combination benefits with standard of care therapies [8].

Nurix's lead BTK degrader, bexobrutideg, demonstrates exceptional efficiency, with a single molecule degrading approximately 10,000 copies of BTK per hour   BRAF degrader demonstrates broad activity across all three BRAF mutation classes Aurora A kinase degraders demonstrate potential to address both enzymatic and scaffolding functions and promote tumor regression in brain and small cell lung cancer models  SAN FRANCISCO, April 25, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (NASDAQ:NRIX), a clinical- ...